시장보고서
상품코드
1290574

세계의 간성뇌증 시장 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별 - 규모, 점유율, 전망, 기회 분석(2023-2030년)

Hepatic Encephalopathy Market, by Drug Class, by Route of administration, By Distribution Channel, by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간성뇌증은 급성 간부전, 간경변, 말기 간질환 환자의 사망 원인 중 가장 높은 비중을 차지합니다. 간성뇌증에 걸리면 암모니아를 대사하는 능력이 상실되어 신체의 여러 조직과 기관에 암모니아가 축적됩니다. 또한 암모니아는 혈액뇌장벽을 통과하여 신경인지장애를 유발합니다. 간성뇌증은 간성뇌증(CHE)과 간성뇌증(OHE)으로 분류되며, 이 중 간성뇌증은 간성뇌증(CHET)에 비해 사망률이 높고 삶의 질이 좋지 않은 것으로 알려져 있습니다. 시장 진출기업들은 간 질환을 치료할 수 있는 새로운 기술과 기법을 개발하고 있습니다. 이에 따라 내년에는 시장이 확대될 것으로 보입니다.

저렴한 간 관련 치료 옵션에 대한 접근성을 향상시키기 위한 정부 및 비정부기구의 이니셔티브가 증가하고 있습니다. 간 건강의 중요성에 대한 사람들의 인식 증가와 유리한 상환은 시장 성장을 가속할 가능성이 높은 요인입니다. 예를 들어, 2022년 10월, Bausch Health Companies Inc.와 위장병 사업부 및 최대 전문 제약사 중 하나인 Salix Pharmaceuticals는 뇌에 영향을 미치는 간경변증의 합병증인 간성뇌증(HE)에 대한 ICD-10 코드 K76.82의 Centers for Medicare &Medicaid Services(CMS)가 간경변증의 합병증인 간성뇌증(HE)에 대한 ICD-10 코드 K76.82의 도입을 지지한다고 발표했습니다.

본 조사의 주요 특징

  • 이 보고서는 2022년을 기준연도로 하여 예측 기간(2023년-2030년) 시장 규모와 연평균 성장률(CAGR)을 제공하는 세계 간성뇌증 시장을 상세하게 분석합니다.
  • 다양한 부문의 잠재적 수익 기회를 파악하고 이 시장에 대한 매력적인 투자 제안 매트릭스를 설명합니다.
  • 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역 전망 및 주요 기업이 채택한 경쟁 전략에 대한 중요한 고려 사항을 제공합니다.
  • 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등 다음과 같은 매개 변수를 기반으로 세계 간성 뇌병증 시장의 주요 기업을 프로파일링합니다.
  • 이 조사에서 다룬 주요 기업은 ASKER Pharmaceutical Co. Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.등입니다.
  • 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전술에 대한 정보에 입각한 의사 결정을 내릴 수 있습니다.
  • 세계 간성 뇌병증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
  • 이해관계자는 세계 간성뇌증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 전망

  • 보고서 개요
    • 시장 정의와 범위
  • 주요 요약
    • 시장 현황 : 약물 클래스별
    • 시장 현황 : 투여 경로별
    • 시장 현황 : 유통 채널별
    • 시장 현황 : 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
  • 영향 분석
  • 주요 발전
  • 최근의 제품 발매/승인
  • 기술적 배경
  • 합병, 인수, 공동 연구 시나리오
  • 법규제 시나리오
  • PEST 분석
  • Porter의 Five Forces 분석
  • 가격 분석
  • 브랜드 분석

제4장 세계의 간성뇌증 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

  • 경제적 영향
  • COVID-19 역학
  • 수요 및 공급에 대한 영향

제5장 세계의 간성뇌증 시장 : 약물 클래스별, 2017년-2030년

  • 항생제
  • 완하제
  • L-ornithine L-aspartate
  • 기타

제6장 세계의 간성뇌증 시장 : 투여 경로별, 2017년-2030년

  • 경구 투여
  • 정맥내 투여
  • 직장

제7장 세계의 간성뇌증 시장 : 유통 채널별, 2017년-2030년

  • 병원내 약국
  • 소매 약국
  • 온라인 약국

제8장 세계의 간성뇌증 시장 : 지역별, 2017년-2030년

  • 북미
  • 미국
  • 캐나다
  • 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
  • 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • ASEAN
  • 한국
  • 기타 아시아태평양
  • 중동 지역
  • GCC
  • 이스라엘
  • 기타 중동
  • 아프리카
  • 북아프리카
  • 중앙아프리카
  • 남아프리카공화국

제9장 경쟁 구도

  • ASKA Pharmaceutical Co., Ltd
  • Cosmo Pharmaceuticals N.V.
  • Lupin Limited.
  • Kaleido Biosciences
  • Kannalife Sciences Inc.
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals Inc
  • Mallinckrodt Pharmaceuticals
  • Umecrine Cognition AB
  • Norgine B.V.
  • Abbott Laboratories
  • QR Science and Technology Development Co.

제10장 섹션

  • 조사 방법에 대해
  • 출판사에 대해
lsh 23.06.30

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood-brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.

Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance, in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain

Key features of the study:

  • This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hepatic encephalopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market

Detailed Segmentation:

  • Global Hepatic Encephalopathy Market, By Drug Class:
    • Antibiotics
    • Laxatives
    • L-ornithine L-aspartate
    • Others
  • Global Hepatic Encephalopathy Market, By Route of administration:
    • Oral
    • Intravenous
    • Rectal
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatic Encephalopathy Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • ASKA Pharmaceutical Co., Ltd.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Cosmo Pharmaceuticals N.V
    • Lupin Limited
    • Kaleido Biosciences
    • Kannalife Sciences Inc.
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • Umecrine Cognition AB
    • Norgine B.V
    • Abbott Laboratories
    • Kos Pharmaceuticals, Inc.
    • QR Science and Technology Development Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Distribution
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Key Developments
  • Recent Product Launches/Approvals
  • Technological Landscape
  • Merger, Acquisition, Collaborations Scenario
  • Regulatory Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Pricing Analysis
  • Brand Analysis

4. Global Hepatic Encephalopathy Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Hepatic Encephalopathy Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Antibiotics
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Laxatives
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • L-ornithine L-aspartate
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Others
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends

6. Global Hepatic Encephalopathy Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Rectal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hepatic Encephalopathy Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • China
  • Japan
  • India
  • Australia
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • ASKA Pharmaceutical Co., Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Cosmo Pharmaceuticals N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Lupin Limited.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kaleido Biosciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kannalife Sciences Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bausch Health Companies Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ferring Pharmaceuticals Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mallinckrodt Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Umecrine Cognition AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Norgine B.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • QR Science and Technology Development Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제